APLM

Apollomics Inc

Jun 16 • 04:00PM ET

14.49

+0.64 4.63 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: SNTI BRNS CRVO GRDX IGC LSTA NRSN PLRZ SER SKYE

Index	-	P/E	-	EPS (ttm)	-7.57	Insider Own	47.33%	Shs Outstand	2.20M	Perf Week	1.34%
Market Cap	31.83M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.16M	Perf Month	-3.39%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	0.03%	Short Float	0.14%	Perf Quarter	-25.69%
Income	-10.94M	P/S	3.74	EPS this Y	-	Inst Trans	-1.45%	Short Ratio	0.19	Perf Half Y	-9.71%
Sales	8.50M	P/B	-	EPS next Y	-	ROA	-110.43%	Short Interest	0.00M	Perf YTD	-22.49%
Book/sh	-	P/C	9.70	EPS next 5Y	-	ROE	-1305.37%	52W High	42.12 -65.60%	Perf Year	123.82%
Cash/sh	1.49	P/FCF	-	EPS past 3/5Y	50.29% 18.23%	ROIC	-	52W Low	3.66 296.04%	Perf 3Y	-97.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.65% 7.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	86.10%	Oper. Margin	-304.27%	ATR (14)	1.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-128.69%	RSI (14)	52.26	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.96	EPS Q/Q	-1224.24%	SMA20	3.05%	Beta	1.53	Target Price	50.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	1.76%	Rel Volume	0.74	Prev Close	13.85
Employees	14	LT Debt/Eq	-	Earnings	Apr 27 BMO	SMA200	-6.95%	Avg Volume	8.44K	Price	14.49
IPO	Nov 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,247	Change	4.63%

Apr-27-26 08:00AM	Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress (GlobeNewswire)
Apr-01-26 07:00AM	Apollomics Inc. Announces $2.0 Million Bridge Financing (GlobeNewswire) -7.13%
Dec-22-25 04:05PM	Apollomics Reports First Half 2025 Financial Results (GlobeNewswire) +10.55% -6.81%
Nov-19-25 05:38PM	Apollomics Announces Settlement of Cayman Litigation (GlobeNewswire) -17.51%
Nov-17-25 11:00PM	Apollomics Announces Changes to its Board of Directors and Composition of Committees (GlobeNewswire) -12.59% -14.50%
02:36PM	Loading…
Oct-15-25 02:36PM	Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation (GlobeNewswire) +5.79%

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

CEO & Chairman of the BoardMr. Hung-Wen Chen

M.B.A.Mr. K. H. Lin C.A.I.A.

Director & COOMr. Yi-Kuei Chen

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Chen Hung-Wen	Chief Executive Officer	Jun 15 '26	Option Exercise	5,000	148,334	Jun 16 05:11 PM
CHU YI-AN	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:09 PM
CHEN HONG-JUNG	Director	Jun 15 '26	Option Exercise	500	3,620	Jun 16 05:08 PM
TSAI HSIEN-SHU	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:05 PM
Chen Yi-Kuei	Chief Operating Officer	Jun 15 '26	Option Exercise	5,000	15,000	Jun 16 05:01 PM
Jan Chen-Huan	Director	Jun 15 '26	Option Exercise	500	1,500	Jun 16 05:01 PM
Huang Ya-Chi	Director	May 17 '26	Option Exercise	500	1,000	May 19 12:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLM

Apollomics Inc

Upgrade your Finviz experience